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Abstract
A subset of lung adenocarcinomas is driven by the EML4-ALK
translocation. Even though ALK inhibitors in the clinic lead to
excellent initial responses, acquired resistance to these inhibitors
due to on-target mutations or parallel pathway alterations is a
major clinical challenge. Exploring these mechanisms of resistance,
we found that EML4-ALK cells parental or resistant to crizotinib,
ceritinib or alectinib are remarkably sensitive to inhibition of
CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib. These
compounds robustly induce apoptosis through transcriptional inhi-
bition and downregulation of anti-apoptotic genes. Importantly,
alvocidib reduced tumour progression in xenograft mouse models.
In summary, our study takes advantage of the transcriptional
addiction hypothesis to propose a new treatment strategy for a
subset of patients with acquired resistance to first-, second- and
third-generation ALK inhibitors.
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Introduction
In non–small-cell lung cancer (NSCLC), small molecule inhibitors
that target mutant kinases have offered unprecedented success in
the management of the disease. One of the most successful
examples is echinoderm microtubule like-4-anaplastic lymphoma
kinase (EML4-ALK)-mutant lung cancer, which affects 4–5% of
lung cancer patients (Gainor et al, 2013). A fusion of ALK with
EML4 (Soda et al, 2007) causes the constitutive activation of the
ALK kinase domain and subsequent oncogenic signalling, typi-
cally through the MAPK, JAK-STAT and PI3K-AKT pathways
(Chiarle et al, 2008). To date, the first-generation ALK inhibitor
crizotinib, second-generation ALK inhibitors ceritinib, alectinib
and brigatinib, and the third-generation ALK inhibitor lorlatinib
have been approved by the Food and Drug Administration (FDA)
for the treatment of patients with lung cancer harbouring the
EML4-ALK translocation. The objective response rate for the ALK
inhibitors crizotinib and alectinib in the clinic surpasses 60%,
while a median progression-free survival of 34 months has been
demonstrated with alectinib (Camidge et al, 2018). However,
patients eventually develop disease progression due to drug
resistance.
A common mechanism of resistance is represented by muta-
tions in the ALK kinase domain that hinder small molecule bind-
ing, such as the G1202R mutation which occurs after alectinib
treatment (Gainor et al, 2016). A multitude of parallel pathways’
alterations can also cause resistance to ALK inhibitors, compen-
sating for the lack of EML4-ALK activity. Usually, these are recep-
tor tyrosine kinases (RTKs), such as EGFR, HER3/4 and c-KIT(Lin
et al, 2017) but they can also be other oncogenes, such as KRAS
(Doebele et al, 2012). Treatment options upon failure of ALK
inhibitors are limited and chemotherapy offers only a short-lived
benefit to these patients whereas the additive benefit of
immunotherapy in this context is still unclear (Pacheco &
Camidge, 2019).
In this study, we discovered a cell cycle dysregulation and a
vulnerability of EML4-ALK lung cancer cells to the pan-CDK inhibi-
tors alvocidib and dinaciclib, as well as the CDK7/12 inhibitor
THZ1. We put forward the idea of testing these inhibitors in the
clinic after ALK inhibitors have failed due to the development of
acquired resistance.
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Results
Pathways dysregulated in crizotinib resistance
To mimic the context of acquired resistance to ALK inhibitors
in vitro, we employed cell lines with acquired resistance to crizo-
tinib (Fig 1A and B), ceritinib and alectinib (Appendix Fig S1A)
obtained by long-term exposure to increasing concentrations of the
drugs. These cell lines were derived from the parental H3122 cells
(Lovly et al, 2011) and STE-1 cells, a patient-derived lung cancer
cell line described in (Lovly et al, 2014), both of which carry the
EML4-ALK (E13;A20) translocation.
As revealed by Sanger sequencing, all the resistant cells have
wild-type ALK kinase domain. Due to the absence of ALK kinase
domain mutations, we reasoned that this lack of response to ALK
inhibition was a result of alterations in parallel signalling. To iden-
tify the driver of crizotinib resistance, we followed a transcriptomic
approach and performed RNA-seq of CrizR1 and isogenic parental
H3122 cells (Dataset EV1). Through this analysis, we detected an
upregulation of the EGFR mRNA that we further validated at the
protein level (Appendix Fig S1B). Increased EGFR signalling,
through ligand upregulation, gene amplification or point mutation,
is to our knowledge the most common ALK-independent mechanism
of resistance to ALK inhibitors (Camidge et al, 2014). To investigate
whether this was the main driver of resistance, we silenced EGFR
by RNAi (Appendix Fig S1C). We asked if this silencing in combina-
tion with crizotinib could re-sensitize CrizR1 cells; however, we
observed no significant induction of apoptosis (Appendix Fig S1D).
We used HCC-827 EGFR-driven cells as positive control, which
indeed became apoptotic upon EGFR silencing. In addition, we
detected an upregulation of the TGF-b receptors 1 and 2
(Appendix Fig S1E) and found that inhibition of TGF-b activity with
the small molecule inhibitor galunisertib resulted only in a marginal
decrease of cell proliferation (Appendix Fig S1F). Ruling out that
EGFR/TGF-bR act as drivers of resistance, we searched for more
dysregulated oncogenes.
Using the HALLMARK gene collection, we found a significant
enrichment in epithelial-to-mesenchymal transition (EMT)-related
genes in CrizR1 cells (Fig 1C and D). Given the mesenchymal
phenotype of the crizotinib-resistant cell lines (Appendix Fig S2A),
we asked whether EMT played a role in these drug-resistant cells.
We chose 4 genes known to induce mesenchymal characteristics
and confirmed their expression levels via qPCR. AXL, LOX, SNAI2
and VIM were upregulated in the majority of the resistant cell lines
(Fig 1E). AXL protein levels were particularly elevated in the CrizR1
and CrizR4 cells and AXL is known to be activated in drug-resistant
EML4-ALK cells (Nakamichi et al, 2018). Interestingly, we detected
a downregulation of ALK in the same cells, raising the possibility
that AXL compensates in part for the reduced EML4-ALK activity.
Moreover, AXL inhibition with the small molecule inhibitor bemcen-
tinib (Holland et al, 2010) resulted in the downregulation of LOX,
SNAI2 and VIM, indicating that AXL activation is responsible for the
induction of these genes and subsequently EMT (Fig 1F). Next, we
asked whether AXL upregulation is functional in these cells and in a
proliferation assay, bemcentinib halted proliferation in CrizR1 and
CrizR4 cells in combination with crizotinib (Fig 1G), suggesting that
AXL activation has a functional role in these cells. However,
bemcentinib alone or in combination with crizotinib did not induce
cell death or senescence (Fig 1H and Appendix Fig S2B), indicating
a cytostatic instead of a cytotoxic effect. In summary, we have
detected an AXL-mediated induction of resistance to crizotinib.
Although AXL inhibitors significantly reduce cell proliferation, they
are unable to kill crizotinib-resistant cells.
Dysregulation of cell cycle-related genes in
crizotinib-resistant cells
In the RNA-seq data comparing crizotinib-resistant versus crizo-
tinib-sensitive cells, a KEGG pathway analysis by GSEA revealed 9
pathways enriched in dysregulated genes (Dataset EV1 and Fig 2A).
Among them, there was a significant enrichment in cell cycle-related
genes (Fig 2A and B, Dataset EV2). We were able to confirm by
immunoblot the upregulation of multiple cell cycle-related genes in
the crizotinib-resistant cells. Notably, CDK1 and CCNB1, as well as
CDK6, were upregulated in the majority of the resistant cell lines
(Fig 2C). CDK2 was not upregulated, but we found an upregulation
▸Figure 1. EMT-related genes are dysregulated in crizotinib-resistant cells.A Table reporting all drug-resistant cell lines used in this study.
B Proliferation assay of H3122 parental and isogenic drug-resistant cells, treated with the indicated concentrations of crizotinib for 72 h. P < 0.0001 was calculated for
IC50 shift as indicated in the Materials and Methods.
C Gene set enrichment analysis after RNA-seq of H3122 sensitive versus CrizR1 crizotinib-resistant cells.
D Epithelial-to-mesenchymal transition enrichment plot from the RNA-seq of C), using the HALLMARK gene collection.
E H3122 parental and drug-resistant isogenic cell lines were RNA-extracted, and gene expression was analysed by RT-qPCR. On the right hand side is a Western blot
analysis of the AXL and EML4-ALK protein levels from the same cell lines.AXL: CrizR1 versus H3122 P < 0.001, CrizR4 versus H3122 P < 0.001, CrizR5 versus H3122
P = 0.03, CeritR versus H3122 P = 0.2; LOX: CrizR1 versus H3122 P < 0.001, CrizR4 versus H3122 P < 0.001, CrizR5 versus H3122 P < 0.001, CeritR versus H3122
P = 0.008; SNAI2: CrizR1 versus H3122 P < 0.001, CrizR4 versus H3122 P < 0.001, CrizR5 versus H3122 P = 0.003, CeritR versus H3122 P = 0.003; VIM: CrizR1 versus
H3122 P < 0.001, CrizR4 versus H3122 P < 0.001, CrizR5 versus H3122 P < 0.001, CeritR versus H3122 P < 0.001.
F Gene expression analysis by RT-qPCR of CrizR1 cells treated with the indicated concentrations of bemcentinib for 48 h. LOX: P = 0.03; SNAI2: P = 0.02; VIM: P = 0.03.
G Proliferation assay of CrizR1 and CrizR4 cells treated with the indicated concentrations of bemcentinib  1 lM crizotinib for 72 h. ***P < 0.001 for IC50 shift, as
indicated in the Materials and Methods (n = 4).
H Annexin V+ apoptotic assay in CrizR1 cells treated with 1 lM crizotinib, 2.5 lM bemcentinib, or combination. STE-1 parental cells were used as crizotinib drug
control. crizotinib: P = 0.2; bemcentinib: P = 0.4; combination: P = 0.3.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD (n = 3, unless otherwise specified).
*P < 0.05, ***P < 0.001, N.S. = Not Significant P > 0.05.
Source data are available online for this figure.
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of its partner CCNE1. In alectinib-resistant cells, CDK1, CCNB1 and
CDK6 were also upregulated (Fig 2D).
With CDK6 being the most strongly upregulated protein, we
hypothesized that pharmacological inhibition of CDK6 would
reverse the resistance to crizotinib. To this end, we used the speci-
fic CDK4/6 inhibitor palbociclib in a proliferation assay and identi-
fied a limited sensitization to crizotinib only at high micromolar
concentration (Fig EV1A). We reasoned that upregulation of CDK6
on its own might not be sufficient to induce crizotinib resistance.
Therefore, we used the CDK inhibitor alvocidib (Flavopiridol), a
potent inhibitor of CDK1, CDK2, CDK4, CDK6 and CDK9, with or
without crizotinib in a proliferation assay. Although alvocidib did
not synergize with crizotinib in CrizR1 cells (Fig 2E and F), we
observed a remarkable sensitivity to single-agent alvocidib in both
parental and isogenic resistant cells (Fig 2G). In addition to the
H3122, which carry the EML4-ALK variant 1, we also tested H2228
cells, which harbour the EML4-ALK v3a/b variant and are primar-
ily more resistant to crizotinib compared with H3122 cells. Alvo-
cidib treatment resulted in comparable inhibition of proliferation
(Fig EV1B).
To follow up on this observation, we also tested dinaciclib, a
newer, more potent CDK1, CDK2, CDK5 and CDK9 inhibitor (Parry
et al, 2010). Both alvocidib and dinaciclib significantly inhibited cell
proliferation at low nanomolar concentrations in EML4-ALK cells
with acquired resistance to these inhibitors as well as the parental
cells (Fig 2H).
We then asked whether CDK1, CDK2 or CDK6 could affect the
resistance to crizotinib individually or in synergy. Upon silencing of
these CDKs (Fig EV1C) and after a cell cycle profile, it was evident
that CDK6 silencing did not affect these cells, while CDK1 silencing
(or silencing of all the three CDKs simultaneously) resulted in arrest
of the cell cycle in the G2/M phase and an induction of cell death as
assessed by DNA content (Fig EV1D and E).
CDK inhibitors induce apoptosis through
transcriptional inhibition
Considering the efficacy of both alvocidib and dinaciclib in inhibit-
ing the transcriptional CDKs, and the preferential activity against
CDK9, we next hypothesized that their pronounced anti-proliferative
activity could be in part due to the suppression of transcription. To
evaluate the transcriptional hypothesis, we used the CDK7/12
inhibitor THZ1 (Kwiatkowski et al, 2014), since CDK7 is also
influencing transcription by phosphorylating the RNA polymerase II
(Blagosklonny, 2004). As with alvocidib, we followed up on the
effectiveness of THZ1 as a single agent. All EML4-ALK cells showed
a remarkable decrease in cell proliferation upon THZ1 treatment
(Fig 3A).
Treatment of the parental, crizotinib-, ceritinib- or alectinib-resis-
tant cells with modest concentrations of alvocidib, dinaciclib or
THZ1 led to near-complete inhibition of cell proliferation as
assessed by crystal violet staining (Fig 3B). These data suggest that
CDK inhibition may target an inherent vulnerability of EML4-ALK
lung cancer and should be further tested.
We next questioned whether this pronounced effect observed
upon treatment with CDK inhibitors was a result of cell cycle arrest
or apoptotic cell death. Alvocidib treatment caused an accumulation
of cells in the G2/M phase assessed by DNA content (Fig EV2A).
Apoptotic cell death was the main outcome of alvocidib and dinaci-
clib treatment in all cell lines tested, assessed via PARP cleavage
(Fig EV2B) as well as Annexin V+/PI staining (Figs 3C and EV2C).
In addition, this induction of apoptosis was not due to toxicity, as
normal lung epithelial HBEC cells did not become apoptotic
(Fig EV3A). Furthermore, there was selectivity towards EML4-ALK
cells, as alvocidib and dinaciclib induced significantly higher levels
of apoptosis in CrizR1 and AlecR cells compared with KRASmut
A549 cells, KRASwt/EGFRmut PC-9 cells or cells isolated from meta-
static sites (H1299 and H460) (Figs 4A and EV3B).
To approach the induction of apoptosis in a more unbiased fash-
ion, we treated CrizR1 cells with alvocidib and used an apoptosis
array that profiled 43 different proteins (Figs 4B and EV3C). We
found an upregulation of critical pro-apoptotic components such as
BIM, BID, SMAC and as expected, CASP3 and CASP8. In agreement
with a previous study (Ma et al, 2003) after alvocidib or dinaciclib
treatment, we observed a downregulation of MCL-1 as well as of the
anti-apoptotic protein BIRC5 (Survivin) in all EML4-ALK cells resis-
tant to all ALK inhibitors (Fig 4C).
We then reasoned that all the three inhibitors affect transcrip-
tional regulation and subsequently the mRNA levels of pro- and
anti-apoptotic proteins. Alvocidib is known to decrease transcrip-
tional output by inhibiting CDK9 and, consequently, elongation by
the RNA Polymerase II (Blagosklonny, 2004). Indeed, in our system,
alvocidib and dinaciclib treatment decreased phosphorylation at the
Ser2 repeat of the RNA Pol II (Fig EV3D). To test the specificity of
these inhibitors, we used siRNAs for CDK7 and CDK9. Only a
modest knockdown of CDK9 was sufficient to induce apoptosis
▸Figure 2. Actionable cell cycle dysregulation in crizotinib-resistant cells.A GSEA enrichment analysis using the KEGG gene set identifiers. Shown are the significantly dysregulated pathways (P < 0.05).
B Cell cycle enrichment plot from (A).
C Western blot analysis of H3122 parental and isogenic drug-resistant cell lines for the indicated proteins.
D Western blot analysis of Ste-1 parental and isogenic alectinib-resistant cell lines for the indicated proteins.
E Proliferation assay of CrizR1 cells treated with the indicated concentrations of alvocidib  1 lM crizotinib for 72 h. P = 0.2 (n = 4).
F As above, in a proliferation assay, H3122 and CrizR1 cells were treated in parallel with DMSO or 1 lM crizotinib as drug control. H3122 versus DMSO P < 0.0001,
CrizR1 versus DMSO P = 0.1 (n = 4).
G, H Proliferation assay of CrizR1, CrizR4, CrizR5, CeritR and AlecR isogenic drug-resistant cell lines, treated with the indicated concentrations of alvocidib (G) or
dinaciclib (H) for 72 h. P > 0.05 was calculated for IC50 shift, as indicated in the Materials and Methods.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD (n = 3, unless otherwise specified).
***P < 0.001, N.S. = Not Significant P > 0.05.
Source data are available online for this figure.
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(Figs 4D and EV3E). Conversely, CDK7 knockdown on its own did
not lead to apoptosis, suggesting a need for combined inhibition of
CDK7/12/13.
Interestingly, levels of some of the previously examined cell
cycle-related genes were upregulated in CrizR1 compared with the
H3122 parental cells and were significantly reduced upon treatment
with alvocidib or the transcription inhibitor actinomycin D, corrobo-
rating the hypothesis of a transcriptional regulation (Fig 4E).
Subsequently, we hypothesized that the short-lived, anti-apop-
totic mRNAs such as MCL-1 and Survivin are degraded after tran-
scriptional inhibition. Consistently, MCL-1 and Survivin were
downregulated at the mRNA level after treatment with all the
compounds (Fig 4F). We asked whether MCL-1 or Survivin down-
regulation was enough to induce apoptosis and to account for alvo-
cidib-induced cell death. We silenced MCL-1 or Survivin using two
different siRNAs for MCL-1 and a pool of 4 different siRNAs for
Survivin, and we observed a significant induction of apoptosis
upon Survivin and not MCL-1 silencing, suggesting that Survivin
downregulation is partly responsible for the apoptotic response to
CDK inhibitors. (Fig 4G and Appendix Fig S3A). To shed light on
the specificity of these compounds towards EML4-ALK cells, we
analysed RNA-seq expression data from the cancer cell line ency-
clopaedia (CCLE) (Ghandi et al, 2019). We used the HALLMARK
apoptosis gene collection and plotted the z-score of the apoptotic
genes in all the lung adenocarcinoma lines (LUAD) (Appendix Fig
S3B). Intriguingly, H3122 cells had the highest expression levels of
Cyclin D1 as well as MCL-1 compared with the rest of the LUAD
cells (Fig 4H and Appendix Fig S3C). Survivin is not part of the
HALLMARK gene set, but when we looked at it separately, we
found that H3122 cells had the highest Survivin mRNA levels
(Fig 4H). Altogether, these findings indicate that treatment with
alvocidib or THZ1 leads to cell death at least in part through
Survivin downregulation.
Effects of alvocidib and THZ1 treatment on transcription
initiation and elongation
In order to add confidence to the transcriptional hypothesis, we
performed ChIP-seq for RNA polymerase II after treating CrizR1
cells with alvocidib or THZ1. A global overview of RNA pol II
peaks suggested that alvocidib treatment dramatically increased
occupancy at the transcription start site (TSS), while THZ1
decreased it (Fig 5A). We performed GSEA analysis based on the
core enrichment of the mapped peaks and found 6 differentially
enriched signatures with alvocidib (Fig 5B) and 11 with THZ1
(Fig 5C). Notably, both drugs induced different RNA pol II occu-
pancy in the TSS of MYC targets. Lastly, we looked at the peaks of
the previously examined genes MCL1, Survivin and CCND1 and we
also included MYC. From the gene tracks, it was evident that alvo-
cidib treatment resulted in pausing of the RNA pol II at the TSS
while reducing the occupancy across the gene bodies, while THZ1
resulted in reduced binding of RNA pol II at the TSS and in the
gene bodies (Fig 5D). This is highly concordant with previous find-
ings which suggest that CDK7 mediates the binding of the RNA pol
II at the promoters while CDK9 regulates the release and elonga-
tion steps (Kwiatkowski et al, 2014). MYC and CCND1 downregula-
tion upon alvocidib or THZ1 treatment was confirmed by qPCR
(Fig 5E). Notably, MYC silencing induced upregulation of the pro-
apoptotic proteins BIM and significantly increased cell death
(Fig 5F and G). Furthermore, MYC indirect inhibition via trame-
tinib, rapamycin or both significantly induced cell death in CrizR1
cells (Fig 5H). In conclusion, transcriptional inhibition with the
described CDK inhibitors offers a new way to induce apoptosis in
EML4-ALK lung cancer cells.
Alvocidib is effective in vivo
To test the activity of alvocidib in vivo, we first characterized the
resistant cells to verify whether they could keep the resistance in
the absence of the drugs for up to 6 weeks. CrizR1, CrizR4 and
AlecR cells showed marked resistance in the absence of crizotinib
for up to 6 weeks (Fig EV4A), although the AlecR cells are primar-
ily more sensitive to the drug compared with the crizotinib-resis-
tant cells. Next, we tested the activity of alvocidib in vivo. As
expected, H3122 xenograft mouse models responded to crizotinib
and alvocidib (Fig EV4B and C). CrizR1 and CrizR4 xenograft
mouse models were resistant to crizotinib while treatment with
alvocidib resulted in reduced tumour growth (Figs 6A and B, and
EV4D and F). We also noticed a significant decrease in tumour
growth in response to alvocidib in mice harbouring alectinib-resis-
tant tumours (Figs 6C and EV4G). Alvocidib treatment was gener-
ally well tolerated, although weight loss was observed in some of
the mice (Appendix Fig S4). Upon sacrificing the mice, we assessed
the apoptotic status of these tumours by in situ immunohistochem-
istry (IHC). The increase in cleaved caspase 3 was evident in
CrizR1 and AlecR tumours (Fig 6D), while in CrizR4 tumours the
levels of cleaved caspase 3 were marginally significant (Fig EV5A).
However, we should note that in the CrizR4 model the absence of
drug treatment during the last week before sacrifice complicates
this interpretation.
In agreement with in vitro studies, in tumours treated with alvo-
cidib we observed downregulation of the marker of proliferation
Ki67 as well of MYC, Survivin and MCL-1, and upregulation of BIM
and p21(Figs 6E and F, and EV5B and C).
These results raised questions in terms of sequential use of ALK
inhibitors. For patients with wild-type ALK who progress on
◀ Figure 3. Cells harbouring the EML4/ALK translocation are remarkably sensitive to alvocidib, dinaciclib and THZ1.
A Proliferation assay of CrizR1, CrizR4, CrizR5, CeritR and AlecR isogenic drug-resistant cell lines, treated with the indicated concentrations of THZ1 for 72 h. P < 0.05
was calculated for IC50 shift, as indicated in the Materials and Methods.
B Crystal violet staining of EML4/ALK parental and drug-resistant cells. Cells were treated with the indicated drugs until the vehicle control reached confluence, then
fixed and stained.
C CrizR1 cells were treated with the indicated drugs for 72 h, and then, cells were stained with Annexin V/PI. Flow cytometry was then used to quantify Annexin V+
cells. Alvocidib: early apoptosis P = 0.002, late apoptosis P = 0.006, alive P = 0.0008; Dinaciclib: early apoptosis P = 0.005, late apoptosis P = 0.02, alive P = 0.002.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD (n = 3). *P < 0.05, **P < 0.01,
***P < 0.001, N.S. = Not Significant P > 0.05.
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crizotinib or alectinib, the third-generation ALK inhibitor lorlatinib
could conceivably be used to more potently inhibit ALK. In a prolif-
eration assay, while H3122 parental cells were very sensitive to
lorlatinib-, crizotinib- and ceritinib-resistant cells were cross-resis-
tant to lorlatinib while they were very sensitive to alvocidib or
dinaciclib (Fig 6G). Alectinib-resistant cells did respond to lorla-
tinib, but they were more sensitive to transcriptional inhibition.
However, resistance of CrizR1 cells to lorlatinib was not confirmed
in vivo in a mouse xenograft model (Figs 6H and EV5D), possibly
due to the high concentration of lorlatinib used in vivo compared
with the concentration used in vitro. Therefore, we propose to use
lorlatinib as second-line therapy in patients with wild-type ALK who
became refractory to crizotinib, and alvocidib when resistance to
ALKi occurs as potential alternative to chemotherapy. In conclusion,
we have presented a potential new alternative to chemotherapy in
the refractory setting (Fig 6I).
Discussion
In this paper, we have found that a global transcriptional dysregula-
tion leads to crizotinib resistance in EML4-ALK cells. Furthermore,
we have shown that transcriptional inhibition is highly potent in
this context and that the CDK inhibitors alvocidib, dinaciclib and
THZ1 warrant clinical testing in patients with disease progression
due to ALK-independent mechanisms of resistance. Specifically, we
have shown that downregulation of key cell cycle proteins as well
as an upregulation of pro-apoptotic proteins mediate the response to
crizotinib.
In our data, even though EGFR overexpression and activation
was present in CrizR1 cells, it did not mediate resistance to crizo-
tinib. This is not surprising, given that a case of crizotinib-resistant
cells with EGFR amplification that had another main driver of
resistance has been reported before (Katayama et al, 2012). TGF-b
inhibition had a marginal effect on the proliferation of crizotinib-
resistant cells, implying that TGF-b activity acts in part to promote
resistance to crizotinib. Furthermore, although AXL inhibition
partially reduced cell proliferation it had no effect in inducing
programmed cell death in ALK+-resistant cells.
Amplification of CDKs or their partner Cyclins has been
described to confer a proliferative advantage to tumour cells (Otto &
Sicinski, 2017). Recent work in EGFR-mutant lung cancer revealed
that amplification of the CCNE1 gene can be found in patients with
acquired resistance to EGFR inhibitors (Blakely et al, 2017) and
specifically with acquired resistance to osimertinib (Yang et al,
2018). We have demonstrated that cells with acquired resistance to
ALK inhibitors present CDKs/Cyclins upregulation. We thereby
observed the impressive single-agent activity of CDK inhibitors that
cannot be explained by single inhibition of CDK1, CDK2 or CDK6,
as evidenced by siRNA experiments. This previously unseen potent
activity of CDK inhibitors at concentrations that are easily achiev-
able in the clinic (Shapiro et al, 2001; Stephenson et al, 2014)
prompted us to investigate this further.
Alvocidib and dinaciclib are known to potently inhibit the tran-
scriptional regulator CDK9 (Parry et al, 2010), while THZ1 inhibits
the transcriptional regulators CDK7/12 (Kwiatkowski et al, 2014).
CDK7/12 and CDK9 regulate transcription by phosphorylating the
RNA polymerase II (Oelgeschla¨ger, 2002). With siRNA experiments,
we were able to induce apoptosis by partial CDK9 downregulation.
CDK7 knockdown did not lead to apoptosis, but it has been
observed before that concurrent inhibition of CDK7/12/13 is
required for an effect on transcription (Olson et al, 2019).
While phosphorylation of RNA pol II at the Ser5 and Ser7 sites
by CDK7 has been shown to be important for the recruitment of the
complex at the TSS (Sampathi et al, 2019), phosphorylation at Ser2
by CDK9 is important for the release and the elongation step
◀ Figure 4. Alvocidib induces cell death through the mitochondrial apoptotic pathway.
A Indicated cell lines were treated with DMSO, 200 nM alvocidib or 25 nM dinaciclib for 48 h, then cells were stained with Annexin V/PI. Flow cytometry was then used
to quantify Annexin V+ cells (n = 2). Alvocidib: CrizR1 P = 0.005, AlecR P = 0.001, PC9 P = 0.05, A549 P = 0.002, H1299 P = 0.03, H460 P = 0.07; Dinaciclib: CrizR1
P = 0.02, AlecR P = 0.005, PC9 P = 0.06, A549 P = 0.08, H1299 P = 0.09, H460 P = 0.01.
B CrizR1 cells were treated with DMSO or 200 nM alvocidib for 24 h, and cell extracts were hybridized to a 43-antibody array and analysed by immunoblotting. Graphs
depict the significant changes from two independent experiments.
C CrizR1/CeritR/AlecR cells were treated with DMSO or 200 nM alvocidib or 50 nM dinaciclib for 6 h and cell extracts were analysed by Western blotting.
D (Top) Western blot analysis of CrizR1 cells treated with siScrambled or siRNA for CDK7 or CDK9 for 72 h. (Bottom) CrizR1 were treated as above, or with
DMSO/alvocidib/THZ1 and cells were stained with Annexin V/PI and analysed by flow cytometry for Annexin V+ cells 72 h post-transfection (n = 2). Annexin siCDK7
P = 0.2, siCDK9 P = 0.015, alvocidib P = 0.0001, THZ1 P = 0.004.
E H3122 parental and CrizR1 cells were treated with DMSO, 200 nM alvocidib or 250 ng/ml actinomycin D for 6 h. RNA was extracted, and the mRNA levels of the
indicated genes were quantified by RT-qPCR. CDK1: DMSO versus H3122 DMSO P = 0.002, Actinomycin versus DMSO P = 0.0003, Alvocidib versus DMSO P = 0.0005;
CDK2: DMSO versus H3122 DMSO P = 0.0001, Actinomycin versus DMSO P < 0.0001, Alvocidib versus DMSO P = 0.0005; CDK6: DMSO versus H3122 DMSO
P = 0.0005, Actinomycin versus DMSO P = 0.0004, Alvocidib versus DMSO P = 0.0004; CDK9: DMSO versus H3122 DMSO P = 0.0003, Actinomycin versus DMSO
P = 0.0002, Alvocidib versus DMSO P = 0.0003; CCNB1: DMSO versus H3122 DMSO P = 0.02, Actinomycin versus DMSO P = 0.0002, Alvocidib versus DMSO
P = 0.0003; CCNE1: DMSO versus H3122 DMSO P = 0.0004, Actinomycin versus DMSO P = 0.0004, Alvocidib versus DMSO P = 0.0005.
F RT-qPCR analysis of MCL-1 and Survivin expression after treatment of CrizR1 cells with 100 nM alvocidib, 25 nM dinaciclib and 50 nM THZ1. RNA was extracted after
24 h of treatment. MCL-1 alvocidib versus control P = 0.0001, dinaciclib versus control P = 0.0001, THZ1 versus control P = 0.0001; Survivin: alvocidib versus control
P = 0.01, dinaciclib versus control P = 0.01, THZ1 versus control P = 0.0001.
G (Top) Western blot analysis of CrizR1 cells treated with siScrambled or with a pool of 4 different siRNAs targeting Survivin (siBIRC5). (Bottom) Cells were stained with
Annexin V/PI and analysed by flow cytometry for Annexin V+ cells 72 h post-transfection. Annexin: early apoptosis P = 0.0003, late apoptosis P = 0.5, alive
P < 0.0001.
H The CCLE RNA-seq data set was used and RPKM values were plotted for the Cyclin D1 and Survivn genes, indicating high expression in H3122 cells compared with
other LUAD cells.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD (n = 3, unless otherwise specified).
*P < 0.05, **P < 0.01, ***P < 0.001, N.S. = Not Significant P > 0.05.
Source data are available online for this figure.
ª 2020 The Authors EMBO Molecular Medicine e11099 | 2020 9 of 16
Athanasios R Paliouras et al EMBO Molecular Medicine
AC
D E
F
G
H
B
Figure 5.
10 of 16 EMBO Molecular Medicine e11099 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Athanasios R Paliouras et al
(Jonkers et al, 2014). Through ChIP-seq, we demonstrated that
alvocidib treatment results in RNA Pol II promoter-proximal paus-
ing, while THZ1 treatment decreases the occupancy of PolII at TSS.
These results suggest that in the described cellular context, inhibi-
tion of CDK7 and CDK9 has a widespread transcriptional effect lead-
ing to downregulation of the transcription factor MYC and its family
members along with several other oncogenes, including CCND1 and
Survivin.
Our proposed model of action for these compounds is an induc-
tion of apoptosis independent of cell cycle arrest since in our data it
is clear that cell cycle arrest is minimal compared with apoptotic
induction. We posit that there is a p53-independent induction of
apoptosis since the parental H3122 cells harbour the E285V inacti-
vating mutation of the TP53 gene (COSMIC project, Sanger Institute
and (Russell-Swetek et al, 2008)). Furthermore, we suggest that the
downregulation of RNA polymerase II activity promotes the loss of
short-lived mRNAs, such as MYC and Survivin (Blagosklonny, 2004)
and an upregulation of pro-apoptotic genes followed by initiation of
apoptosis and specifically of the mitochondrial apoptotic pathway.
Notably, the increase of the pro-apoptotic gene BIM in this context
appears to be, at least in part, MYC-dependent.
We confirmed that alvocidib and dinaciclib induced significantly
higher levels of apoptosis in crizotinib-resistant cells compared with
KRASmut and metastatic NSCLC cell lines or non-transformed
epithelial cells. This could explain why, in terms of clinical testing,
alvocidib was not effective in a previous clinical trial on advanced
metastatic NSCLC (Shapiro et al, 2001). Dinaciclib was shown to be
inactive as monotherapy in patients with NSCLC previously treated
with erlotinib (Stephenson et al, 2014). However, the ALK muta-
tional status in these patients was not assessed; therefore, the trial
did not test the patient cohort that our data would represent, namely
patients with EML4-ALK NSCLC. Consistent with the compelling
in vitro activity, alvocidib was also active in xenograft models of
crizotinib and alectinib resistance, where ALK inhibitors failed. To
our knowledge, this is the first time this has been demonstrated in a
xenograft mouse model of lung adenocarcinoma.
In conclusion, we have reinforced the idea that the appearance of
a known oncogene as mutated or over-activated does not necessar-
ily mean that this oncogene is the main driver of drug resistance.
We have shown multiple alterations that concurrently occur in the
resistance to ALK inhibitors. This complicates the diagnostic setting
and suggests that testing for individual ALK-independent mecha-
nisms of resistance in the clinic could be inefficient. We can there-
fore envision that a more efficient way to address off-target TKI
resistance is either with rational upfront combinations that aim to
prevent it altogether (Hrustanovic et al, 2015; Rusan et al, 2018), or
using a drug with universal activity able to dampen parallel onco-
genic pathways simultaneously.
◀ Figure 5. Alvocidib or THZ1 treatment is concordant with CDK9 or CDK7 inhibition based on RNA polymerase II ChIP-seq.A CrizR1 cells were treated with vehicle control, 200 nM alvocidib or 100 nM THZ1 for 6 h, then chromatin was precipitated with an anti-RNA polymerase II
antibody and sequenced. Plotted is the average number of peaks per condition.
B, C GSEA analysis using the HALLMARK gene collection for the differentially enriched peaks around the TSS (1 kb) with (B) alvocidib or (C) THZ1 treatment. Shown on
the right is the plot of the “MYC targets”-enriched signature.
D Gene tracks of RNA polymerase II occupancy at the MCL1, BIRC5 (Survivin), CCND1 and MYC genes.
E qPCR of MYC and CCND1 upon treatment of CrizR1 cells with Alvocidib or THZ1 for 6 h. The graph represents the mean fold change  SD. MYC: alvocidib versus
DMSO P = 0.03, THZ1 versus DMSO P < 0.0001; CCND1: alvocidib versus DMSO P = 0.001, THZ1 versus DMSO P = 0.003.
F BIM is upregulated upon MYC silencing in CrizR1 cells.
G Annexin V assay showing the percentage of apoptotic CrizR1 cells upon MYC downregulation using siRNA. Early apoptosis P = 0.002, late apoptosis P = 0.04, alive
P = 0.0008.
H Annexin V assay showing the percentage of apoptotic CrizR1 cells after treatment with trametinib, rapamycin or both. Trametinib: early apoptosis P = 0.002, late
apoptosis P = 0.05, alive P = 0.009; rapamycin: early apoptosis P = 0.04, late apoptosis P = 0.8, alive P = 0.003; tram+rapa: early apoptosis P = 0.0001, late
apoptosis P = 0.04, alive P = 0.01.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD (n = 3, unless otherwise specified).
*P < 0.05, **P < 0.01, ***P < 0.001.
Source data are available online for this figure.
▸Figure 6. Alvocidib reduces tumour growth in vivo.A, B Tumour growth of in vivo xenografts of H3122 CrizR1 cell lines in response to crizotinib or alvocidib and correspondent tumour weights (P.O. control n = 5; I.P.
control n = 4; crizotinib n = 8 and alvocidib n = 6). Tumour weights, crizotinib P = 0.44, alvocidib P = 0.03.
C Tumour growth of in vivo xenografts of Ste-1 AlectR cell lines in response to alvocidib and correspondent tumour weights (I.P. control n = 6; alvocidib n = 4).
Tumour weights alvocidib P = 0.004.
D Number of cleaved caspase-3-positive nuclei in alvocidib treated tumours compared with controls.
E Ki67 and p21 staining of CrizR1 xenograft tumours. Scale bar = 200 lm. Quantitative analysis of IHC staining is presented on the right. Ki67 P = 0.0004; p21
P = 0.02.
F qPCR of Survivin (P = 0.0009), MCL-1 (P = 0.04), MYC (P = 0.007) and BIM (P = 0.03) in Ste-1 AlectR cells xenografts treated with alvocidib (Control n = 6; alvocidib
n = 4).
G Proliferation assay of H3122 parental and isogenic drug-resistant cell lines, treated with DMSO, 100 nM lorlatinib, 200 nM alvocidib or 50 nM dinaciclib for 72 h
(n = 4).
H Growth curve of CrizR1 xenograft tumours in response to lorlatinib (Control n = 7; lorlatinib n = 7).
I Model suggesting the clinical sequencing of CDK inhibitors post-ALK inhibition failure as a potential alternative to chemotherapy.
Data information: Statistical comparisons were performed using a paired, two-tailed Student t-test. Plotted graphs show mean  SD. *P < 0.05, **P < 0.01,
***P < 0.001, N.S. = Not Significant P > 0.05.
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Materials and Methods
Apoptotic assay
Annexin V/PI
Cells were trypsinized and processed with a TACS Annexin V/PI
kit (Trevigen) according to the manufacturer’s instructions. Samples
were then run through a NovoCyte flow cytometer (ACEA bios-
ciences) and quantified for Annexin V+ cells. Spectral overlap was
compensated with unstained and single stained controls. Plots were
gated to exclude cell debris and cell doublets.
Senescence assay
Cellular senescence was detected measuring the activity of the b-Galac-
tosidase (b-Gal) using CellEvent Senescence Green Detection kit (Invit-
rogen). 2,000 cells/well were plated in Nunc 96-well optical plates. At
72 h after treatments, cells were washed with PBS, fixed by adding
100 ll/well of fixation solution for 10 min and then washed again with
100 ll of 1% BSA in PBS. Next, 100 ll/well of the pre-warmed working
solution, containing the fluorescence-based b-gal substrate, were added
to each well and incubated for 2 h at 37°C. Cells were washed 3 times
with PBS and, finally, fluorescence by b-gal-cleaved substrate was
measured at 488 nm with M5 SpectraMax plate reader.
Cell culture
HEK293T cells were maintained in DMEM with 1 g/l glucose
(Gibco) + 10% fetal bovine serum (Gibco). HBEC cells were main-
tained in Airway Epithelial Cell Basal Medium (ATCC) combined
with a Bronchial Epithelial Cell Growth kit (ATCC). All the other cell
lines were maintained in RPMI-1640 (Gibco) + 10% fetal bovine
serum (Gibco).
HEK293T and A549 cells were a kind gift from Dr. John Brog-
nard. H1299 cells were a kind gift from Prof. Angeliki Malliri. HBEC,
H2228 and H460 cells were purchased from ATCC. The following
cell sources have been described before: H3122 (Lovly et al, 2011),
STE-1 (Lovly et al, 2014), PC-9 and isogenic cell lines (Meador et al,
2015), H1975 and isogenic cell lines (Meador et al, 2015). H3122
and STE-1 parental cells were STR-profiled upon receipt and found
to be free of contamination with another line. All cell lines were
routinely monitored for mycoplasma contamination using an in-
house Core Facility service.
Drug-resistant cell lines
Full information for drug-resistant cells can be found in Fig 1A.
Briefly, the parental cell lines were exposed to a low concentration
of the primary inhibitor until cells could proliferate fully in the pres-
ence of it. Then cells were split and exposed to 20% higher concen-
tration. The process was repeated until the corresponding cell lines
were resistant to > 500 nM of the primary inhibitor and were then
maintained by adding drug after every passage.
Characterization of resistant cell lines
The capacity of the cells to maintain resistance to crizotinib and
alectinib was assessed over a period of 6 weeks. Briefly, resistant
cell lines (CrizR1, CrizR4 and AlecR) were split to generate a subline
of cells cultured in the absence of drug (drug), in parallel to the
original resistant cell line cultured in the presence of the drug
(+drug). Cell viability was assessed every week until 6 weeks upon
treatment with crizotinib (1 lM) or alectinib (500 nM) for 72 h.
Cell cycle analysis
After the corresponding treatment, cells were fixed in 70% ethanol
and stained with an FxCycleTM PI/RNase Staining Solution (Molecu-
lar Probes). Cell cycle plots were generated in a Novocyte instru-
ment using the device’s software.
Compounds used
Crizotinib, ceritinib, alectinib, erlotinib, osimertinib, palbociclib,
alvocidib, dinaciclib, THZ1, galunisertib and trametinib for in vitro
experiments were all purchased from Selleck. Lorlatinib was
purchased from MedChemExpress. Bemcentinib (R428) was
purchased from Axon. Rapamycin was purchased from Caymen
Chemical. Actinomycin D was purchased from Sigma. Alvocidib,
dinaciclib, crizotinib, lorlatinib and THZ1 for in vivo studies were
purchased from MedChemEexpress whereas alectinib was
purchased from Selleck.
Computational analyses
GSEA
Gene set enrichment analysis was performed by ranking the gene
sets after differential expression analysis of RNA-seq data. The cut-
off for the final list of genes was P adj < 0.05 and log2foldchange
> 1 or < 1. The.rnk files were loaded to the supplied desktop
GSEA v2.0 software (Subramanian et al, 2005). The analysis param-
eters were based on 1,000 permutations and a minimum of 15 genes
per identified set. The individual gene set collections used are
described in the text or figure legends.
Heatmap
Heatmap was generated using the R Package pHeatmap based on
Euclidean distance clustering.
Crystal violet staining
Cells were treated in 6-well plates, fixed for 20 min in 3.7%
paraformaldehyde and then stained for 20 min in a 0.05% crystal
violet solution (Sigma).
In vivo xenograft studies
Female athymic nude mice or NOD-SCID mice from Charles River
were used at 6–8 weeks old. After acclimatization, mice were
injected with 2 million H3122 cells in 50% matrigel, or 2 million
CrizR1 cells in 50% matrigel, 2.5 million CrizR4 cells or 5 million
AlecR cells in 50% matrigel (Corning). When tumours reached
between 100 and 200 mm3, mice were randomized in different
groups.
H3122/CrizR1 experiment: 10 ml/kg vehicle control by oral
gavage daily (n = 5), 50 mg/kg crizotinib by oral gavage daily
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(n = 8), 10 ml/kg vehicle control by I.P. injection 3× a week
(n = 5), 10 mg/kg alvocidib by I.P. injection 3× a week (n = 8). In
the H3122 experiment, the tumour size of the control group and the
gavage group were combined in the graph to facilitate comparison
with crizotinib. For the CrizR1 experiment, measurements shown
are 3 days before sacrifice.
CrizR4 experiment: Initially, mice were randomized to receive
10 ml/kg vehicle control (n = 8) or 10 mg/kg alvocidib (n = 8), by
I.P. injection, daily for 3 weeks. In the crizotinib group, mice were
treated with 10 ml/kg vehicle control or 50 mg/kg crizotinib daily,
by oral gavage.
AlecR experiment: Initially, mice were randomized to receive
10 ml/kg vehicle control by I.P. injection 3×/week (n = 7), 10 mg/
kg alvocidib by I.P. injection 3×/week (n = 7). After 3 weeks of
consecutive treatment, a 1 week on/1 week off pattern was adopted
for the alvocidib/I.P. control group.
CrizR1 experiment with lorlatinib treatment: 10 ml/kg vehicle
control by oral gavage daily (n = 8), 5 mg/kg lorlatinib by oral
gavage daily (n = 8).
Tumours were measured with a digital calliper, and volumes
were calculated using the formula [volume = (width)2 (length)/2.
In all the experiments, mice that showed weight loss > 20% of body
weight or with tumours that reached a size of 1,500 mm3 or that
developed tumour ulceration/bleeding were sacrificed and
discounted from the graphs from that point onwards. In all experi-
ments, mice in the control group that did not develop tumours
bigger than 300 mm3 by the end of the study were discounted.
Crizotinib and alvocidib were dissolved in 5% DMSO, 40% PEG300
and 55% sterile PBS, and the same mix was used as vehicle control.
All procedures involving animals were approved by the CRUK
Manchester Institute’s Animal Welfare and Ethical Review Body.
IHC
Tumours in formalin were embedded in paraffin blocks, and dif-
ferent slices were obtained. Slides were incubated with an anti-
cleaved caspase-3 antibody (Cell Signaling (#9661) at 1/100 dilu-
tion; anti-p21 (Abcam #109520) at 1/100 dilution and anti-Ki67
(Abcam #15580). This was run on a Leica bond Rx with the Refine
Kit with an added casein blocking step with the antigen retrieval
ER1 at pH 6 for 20 min.
Quantification
One section per tumour was imaged at 20×, and the number of
stain-positive cells was quantified in 5 random fields (One field
contains approximately 1,600 cells). The mean number of positive
cells was then plotted.
RNA isolation
RNA was isolated using TRIzol Reagent (Ambion), according to
the manufacturer’s protocol.
RNA profiling
RNA-sequencing
Poly-A: Poly-A libraries were prepared with a SureSelect PolyA kit
(Agilent). RNA-seq reads were quality checked and aligned to the
human genome assembly (GRCh37/hg19). Differential expression
(DE) was evaluated using the DESeq2 package.
ChIP-seq
CrizR1 cells (100 × 106 per condition) were treated with DMSO,
200 nM alvocidib or 100 nM THZ1 for 6 h. Then, chromatin was
isolated according to the published protocol (Nelson et al, 2006) using
10 lg of total RNA polymerase II antibody (Diagenode, #C15200004).
Then, purified chromatin was used as input to generate PCR-amplified
libraries using the Diagenode Microplex kit according to the manufac-
turer’s instructions. The library was sequenced on a Nextseq500 instru-
ment (Illumina) using paired-end sequencing at a sequencing depth of
60–80 million reads per sample. Afterwards, the quality of the
sequenced reads was assessed by the FastQC (Babraham Institute
2010)/fastq-screen (Babraham Institute 2011) output supplied by the
CRUK computational biology facility. Reads were filtered using Trim-
momatic v0.36 (Bolger et al, 2014), to remove any remaining adapter
sequences, poor quality 50 ends of reads or reads shorter than 35
nucleotides. Reads were then mapped to the human genome (UCSC
GRCh38/hg38 analysis set) using Bowtie2 v2.3.0 (Langmead & Salz-
berg, 2012). Mapped reads were filtered to retain concordant read pairs
with a mapping quality of at least 30, using samtools v1.9 (Li et al,
2009 The Sequence Alignment/Map format and SAMtools). The peaks
were called by the use of MACS2 v2.1.2 (Zhang et al, 2008) with the
default parameters. Only binding regions with a Qvalue of < 0.05 were
considered. Differential binding analysis was performed using diffReps
v1.55.6 (Shen et al, 2013) using the midpoint coordinate of the filtered
mapped paired-reads, with fragment size set to 0. RnaChipIntegrator
https://github.com/fls-bioinformatics-core/RNAChipintegrator was
used to identify the closest gene within 100 K of each peak; the distance
being calculated between the closest edge of the summit region and the
TSS of each gene.
RT-qPCR
Total RNA was extracted using TRIzol. For gene-specific qPCR,
200 ng of total RNA were used as input with the Verso cDNA
synthesis kit (Thermo Fisher Scientific) according to the manufac-
turer’s protocol. Then, 1 ll cDNA from each reaction was amplified
with the FS Universal SYBR Green Master Rox master mix (Roche).
The reaction was run on a LightCycler 96 instrument (Roche) and
normalized for relative expression using either ACTB (b-actin)or
GAPDH as housekeeping genes. All the primers used were custom-
designed and can be found in Table EV1.
Proliferation assay
3,000–5,000 cells were plated in 96-well plates and cell proliferation
was assessed by adding 20 ll/well of the CellTiter 96 Aqueous
Non-Radioactive Cell Proliferation reagent (Promega). Absorbance
was recorded at 490 nm using a SpectraMax plate reader. Absor-
bance was normalized to the control and was fitted using a non-
linear regression curve (Prism 7, GraphPad).
Statistical analysis
All statistics and graphs were generated using Prism 7 (GraphPad).
Plotted graphs show mean  SD from 3 biological replicates for all
14 of 16 EMBO Molecular Medicine e11099 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Athanasios R Paliouras et al
experiments unless indicated otherwise in the figure legend. Statisti-
cal comparisons were performed using a paired, two-tailed Student t-
test where *P < 0.05, **P < 0.01 and ***P < 0.001, N.S. = Not
Significant. For linear regression analyses (indicated in the legends),
values were log-transformed and normalized, and then curves were
compared for IC50 difference with an extra-sum-of-squares F-test.
For RNA-seq analysis, the resulting P-values were adjusted using
the Benjamini and Hochberg approach. Genes with an adjusted P-
value determined to be < 0.05 (FDR < 0.05) by DESeq2 and that
had a fold change value ≥ 1.5 (|Log2 fold change| ≥ 0.55) between
two groups were considered to be differentially expressed.
Transfection
All transfection experiments were performed using Lipofectamine
2000 or Lipofectamine RNAiMax (Invitrogen). Smartpool siRNAs for
EGFR, CDK1, CDK2, CDK6, CDK7 and CDK9 or siRNA controls were
obtained from Dharmacon and transfected at 33–100 nM final
concentration. siRNAs for MCL-1 were obtained from Qiagen and
transfected at 25 nM final concentration. A pool of 4 different
siRNAs (SMARTpool) for Survivin were purchased from Dharmacon
and transfected at 100 nM final concentration.
Western blotting
Protein extracts were isolated using a RIPA buffer (Sigma Aldrich)
and quantified with the use of the BCA-pierce assay (Thermo Fisher).
30–50 lg of proteins were combined with a NovexTM Tris-Glycine SDS
Sample Buffer (2×) (Invitrogen) and NuPAGETM Sample Reducing
Agent (10×) (Invitrogen). Samples were then heated at 70°C for
10 min. Afterwards, samples were loaded to either 4–12% or 3–8%
NuPage gels (Invitrogen) and run with NuPAGETM MOPS SDS or
NuPAGETM Tris-Acetate SDS Running Buffer (Invitrogen). Proteins
were then transferred to a PVDF membrane (Immobilon) and blocked
in 5% non-fat dry milk. Membranes were then incubated O/N at 4°C
with the indicated antibodies. Membranes were then incubated with
secondary HRP-conjugated antibodies (Amersham) and developed
using a WesternBright ECL Spray (Advansta). Chemiluminescence
was recorded in a Bio-Rad Chemidoc instrument. The antibodies used
can be found in Table EV1. For the apoptotic array, the assay was
performed according to the manufacturer’s instructions (Abcam).
Data availability
The data sets produced in this study are available in the following
databases: RNA-seq data: Array Express repository E-MTAB-8590
(https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8590);
Chip-Seq data: Array Express repository E-MTAB-8380 (https://
www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8380).
Expanded View for this article is available online.
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